Covaxin gets WHO’s emergency use nod
04/11/2021
According to information released by the WHO, Covaxin was found to have 78% efficacy against COVID-19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to its easy storage requirements.
Health Minister Mansukh Mandaviya, welcoming the announcement, said, “This is a proud moment for the entire country.”
The WHO in its tweets on Wednesday said that the Technical Advisory Group, convened by the WHO and made up of regulatory experts from around the world, has determined that the Covaxin vaccine meets the WHO’s standards for protection against COVID-19; that the benefit of the vaccine far outweighs risks; and that the vaccine can be used.
It added that Covaxin vaccine was also reviewed by the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE).
Dr. Krishna Ella, chairman and MD, Bharat Biotech, said, “Validation by the WHO is a very significant step towards ensuring global access to India’s widely administered, safe and efficacious Covaxin.”
No comments:
Post a Comment